Zentalis Pharma Analyst Ratings
Wells Fargo Downgrades Zentalis Pharmaceuticals to Equal Weight From Overweight, Lowers Price Target to $9 From $29
Assessing Zentalis Pharmaceuticals: A Balanced Hold Rating Amidst Financial Stability and Uncertain Market Prospects
Buy Rating on Zentalis Pharmaceuticals Amid High Expectations for Azeno Drug Trials
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Zentalis Pharmaceuticals (ZNTL) and Paragon 28 (FNA)
Stifel Nicolaus Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharma Analyst Ratings
HC Wainwright & Co. Maintains Buy on Zentalis Pharma, Lowers Price Target to $40
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating
Zentalis Pharma Analyst Ratings
Stifel Maintains Buy on Zentalis Pharma, Lowers Price Target to $32
Buy Rating on Zentalis Pharmaceuticals: Strategic Developments and Multi-Cancer Treatment Potential of Azenosertib
Zentalis Pharmaceuticals: A Cautious Hold Amidst Speculative Opportunities and Upcoming Clinical Updates
HC Wainwright & Co. Reiterates Buy on Zentalis Pharma, Maintains $46 Price Target
Zentalis Pharma Analyst Ratings
Oppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
Buy Rating Affirmed for Zentalis Pharmaceuticals on Strategic Positioning and Clinical Prospects in Ovarian Cancer Treatment
Buy Rating on Zentalis Pharmaceuticals Amidst Undervalued Share Price and Promising Clinical Developments
TD Cowen Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals (ZNTL) Receives a Buy From Stifel Nicolaus